Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences
Ltd is in the business of Pharmaceutical Products
- Market Cap ₹ 27.2 Cr.
- Current Price ₹ 6.79
- High / Low ₹ 17.9 / 5.70
- Stock P/E 31.6
- Book Value ₹ 1.21
- Dividend Yield 0.00 %
- ROCE 10.9 %
- ROE 15.8 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 5.60 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.39%
- Company has a low return on equity of 9.87% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 256 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|
0.00 | 3.46 | 6.44 | 2.66 | 9.56 | 9.89 | 10.39 | 17.81 | 31.65 | |
0.06 | 3.77 | 5.84 | 2.68 | 9.90 | 9.80 | 10.45 | 17.14 | 30.44 | |
Operating Profit | -0.06 | -0.31 | 0.60 | -0.02 | -0.34 | 0.09 | -0.06 | 0.67 | 1.21 |
OPM % | -8.96% | 9.32% | -0.75% | -3.56% | 0.91% | -0.58% | 3.76% | 3.82% | |
0.00 | 0.04 | 0.00 | 0.00 | 0.57 | 0.51 | 0.83 | 0.48 | 0.20 | |
Interest | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.43 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
Profit before tax | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.12 | 0.33 | 0.72 | 0.98 |
Tax % | 0.00% | 0.00% | 13.04% | 0.00% | 0.00% | 41.67% | 0.00% | 16.67% | |
-0.06 | -0.31 | 0.21 | -0.44 | -0.21 | 0.08 | 0.33 | 0.60 | 0.86 | |
EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.21 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 23% |
TTM: | 105% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 69% |
TTM: | 10% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 28% |
3 Years: | -20% |
1 Year: | -64% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 10% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.19 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Reserves | -0.16 | -0.47 | -0.27 | -0.71 | -0.92 | -0.84 | -0.51 | 0.09 | 0.85 |
0.50 | 0.90 | 1.32 | 1.48 | 0.39 | 0.36 | 5.51 | 8.00 | 5.26 | |
0.11 | 2.73 | 5.10 | 6.33 | 8.89 | 4.93 | 6.56 | 10.39 | 18.53 | |
Total Liabilities | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 28.64 |
0.00 | 2.31 | 2.31 | 2.31 | 2.31 | 2.32 | 2.32 | 2.31 | 2.32 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
0.64 | 4.85 | 7.84 | 8.79 | 10.05 | 6.13 | 13.24 | 20.17 | 26.32 | |
Total Assets | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 28.64 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
0.00 | -2.07 | -0.09 | 0.86 | 2.98 | -3.08 | 2.47 | -0.95 | |
0.00 | 1.90 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | |
0.00 | 0.39 | -0.55 | -0.89 | -2.75 | 2.80 | -2.48 | 1.03 | |
Net Cash Flow | 0.00 | 0.23 | -0.64 | -0.03 | 0.22 | -0.30 | -0.01 | 0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 266.89 | 287.35 | 782.14 | 249.70 | 230.66 | 275.42 | 255.77 | |
Inventory Days | 215.20 | 150.49 | 309.32 | 38.07 | 25.93 | 91.82 | 54.64 | |
Days Payable | 304.36 | 319.46 | 878.47 | 319.47 | 153.98 | 207.06 | 211.26 | |
Cash Conversion Cycle | 177.72 | 118.38 | 212.99 | -31.71 | 102.61 | 160.18 | 99.15 | |
Working Capital Days | 388.21 | 281.12 | 592.78 | 116.07 | 117.36 | 204.81 | 185.06 | |
ROCE % | -10.48% | 12.66% | -0.41% | 5.58% | 16.88% | 12.14% | 10.91% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Vivanza Biosciences Limited is a specialty pharma company focused on commercializing novel and generic pharmaceuticals, developing oral drug delivery systems, and having expertise in complex oral and topical dose forms including highly potent compounds, modified release products & injections